- Home
- IDYA vs TFIN Comparison
IDYA vs TFIN Comparison
Compare IDYA & TFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- TFIN
- Stock Information
- Founded
- IDYA 2015
- TFIN 1981
- Country
- IDYA United States
- TFIN United States
- Employees
- IDYA N/A
- TFIN N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- TFIN Major Banks
- Sector
- IDYA Health Care
- TFIN Finance
- Exchange
- IDYA Nasdaq
- TFIN Nasdaq
- Market Cap
- IDYA 1.5B
- TFIN 1.3B
- IPO Year
- IDYA 2019
- TFIN N/A
- Fundamental
- Price
- IDYA $21.22
- TFIN $57.29
- Analyst Decision
- IDYA Strong Buy
- TFIN Hold
- Analyst Count
- IDYA 12
- TFIN 6
- Target Price
- IDYA $54.27
- TFIN $68.50
- AVG Volume (30 Days)
- IDYA 1.5M
- TFIN 220.0K
- Earning Date
- IDYA 05-06-2025
- TFIN 07-16-2025
- Dividend Yield
- IDYA N/A
- TFIN N/A
- EPS Growth
- IDYA N/A
- TFIN N/A
- EPS
- IDYA N/A
- TFIN 0.37
- Revenue
- IDYA $7,000,000.00
- TFIN $401,390,000.00
- Revenue This Year
- IDYA $68.39
- TFIN $12.09
- Revenue Next Year
- IDYA $324.54
- TFIN $14.37
- P/E Ratio
- IDYA N/A
- TFIN $154.96
- Revenue Growth
- IDYA N/A
- TFIN 0.68
- 52 Week Low
- IDYA $13.45
- TFIN $42.90
- 52 Week High
- IDYA $44.42
- TFIN $110.58
- Technical
- Relative Strength Index (RSI)
- IDYA 65.40
- TFIN 48.57
- Support Level
- IDYA $19.26
- TFIN $52.77
- Resistance Level
- IDYA $20.46
- TFIN $61.11
- Average True Range (ATR)
- IDYA 1.01
- TFIN 2.54
- MACD
- IDYA 0.24
- TFIN -0.33
- Stochastic Oscillator
- IDYA 99.55
- TFIN 44.49
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About TFIN Triumph Financial Inc.
Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.